Display options
Cite
Wilms C, Kroeger CM, Hainzl AV, et al. MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget. 2017;8(40):67287-67299doi: 10.18632/oncotarget.18617.
Wilms, C., Kroeger, C. M., Hainzl, A. V., Banik, I., Bruno, C., Krikki, I., Farsam, V., Wlaschek, M., & Gatzka, M. V. (2017). MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget, 8(40), 67287-67299. https://doi.org/10.18632/oncotarget.18617
Wilms, Christina, et al. "MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth." Oncotarget vol. 8,40 (2017): 67287-67299. doi: https://doi.org/10.18632/oncotarget.18617
Wilms C, Kroeger CM, Hainzl AV, Banik I, Bruno C, Krikki I, Farsam V, Wlaschek M, Gatzka MV. MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget. 2017 Jun 27;8(40):67287-67299. doi: 10.18632/oncotarget.18617. eCollection 2017 Sep 15. PMID: 28978033; PMCID: PMC5620173.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 27;8(40):67287-67299. doi: 10.18632/oncotarget.18617. eCollection 2017 Sep 15.

MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth.

Oncotarget

Christina Wilms, Carsten M Kroeger, Adelheid V Hainzl, Ishani Banik, Clara Bruno, Ioanna Krikki, Vida Farsam, Meinhard Wlaschek, Martina V Gatzka

Affiliations

  1. Department of Dermatology and Allergic Diseases, Ulm University, 89081 Ulm, Germany.
  2. ETH, 8092 Zurich, Switzerland.
  3. Department of Neurology, Ulm University, 89081 Ulm, Germany.

PMID: 28978033 PMCID: PMC5620173 DOI: 10.18632/oncotarget.18617

Abstract

Histone modifying enzymes, such as histone deacetylases (HDACs) and polycomb repressive complex (PRC) components, have been implicated in regulating tumor growth, epithelial-mesenchymal transition, tumor stem cell maintenance, or repression of tumor suppressor genes - and may be promising targets for combination therapies of melanoma and other cancers. According to recent findings, the histone H2A deubiquitinase 2A-DUB/Mysm1 interacts with the p53-axis in hematopoiesis and tissue differentiation in mice, in part by modulating DNA-damage responses in stem cell and progenitor compartments. Based on the identification of alterations in skin pigmentation and melanocyte specification in Mysm1-deficient mice, we hypothesized that MYSM1 may be involved in melanoma formation. In human melanoma samples, expression of MYSM1 was increased compared with normal skin melanocytes and nevi and co-localized with melanocyte markers such as Melan-A and c-KIT. Similarly, in melanoma cell lines A375 and SK-MEL-28 and in murine skin, expression of the deubiquitinase was detectable at the mRNA and protein level that was inducible by growth factor signals and UVB exposure, respectively. Upon stable silencing of

Keywords: UV-radiation; epigenetics; melanoma; pigmentation; transcriptional regulation

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

References

  1. Oncogene. 2015 Sep 17;34(38):4964-74 - PubMed
  2. Oncotarget. 2016 Dec 13;7(50):83554-83569 - PubMed
  3. Mol Cell. 2007 Aug 17;27(4):609-21 - PubMed
  4. Hum Mutat. 2007 Jun;28(6):578-88 - PubMed
  5. Cold Spring Harb Perspect Med. 2014 Sep 02;4(9):a015388 - PubMed
  6. Cancer Res. 2001 Feb 1;61(3):823-6 - PubMed
  7. Cell Death Differ. 2015 Sep;22(9):1451-62 - PubMed
  8. Oncogene. 2008 Jan 24;27(5):565-73 - PubMed
  9. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4213-8 - PubMed
  10. Cancer Discov. 2015 Dec;5(12 ):1314-27 - PubMed
  11. Clin Cancer Res. 2007 Apr 1;13(7):2246-53 - PubMed
  12. Oncogene. 2016 Aug 25;35(34):4423-36 - PubMed
  13. Nat Commun. 2015 Jan 22;6:6051 - PubMed
  14. Blood. 2015 Apr 9;125(15):2344-8 - PubMed
  15. Cell Death Differ. 2016 May;23 (5):759-75 - PubMed
  16. Pigment Cell Melanoma Res. 2010 Apr;23 (2):225-37 - PubMed
  17. Mol Cell. 2015 May 7;58(3):468-82 - PubMed
  18. PLoS Genet. 2013;9(7):e1003644 - PubMed
  19. Blood. 2012 Feb 9;119(6):1370-9 - PubMed
  20. J Allergy Clin Immunol. 2015 Dec;136(6):1619-1626.e5 - PubMed
  21. Nat Commun. 2014 Apr 11;5:3540 - PubMed
  22. PLoS One. 2011;6(12 ):e29379 - PubMed
  23. Exp Cell Res. 2014 Nov 15;329(1):148-53 - PubMed
  24. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1720-5 - PubMed
  25. Pigment Cell Melanoma Res. 2012 May;25(3):343-53 - PubMed
  26. J Cell Physiol. 2015 Nov;230(11):2626-33 - PubMed
  27. Exp Dermatol. 2016 Nov;25(11):831-838 - PubMed
  28. Genes Dev. 2016 Jan 1;30(1):18-33 - PubMed
  29. Blood. 2013 Oct 17;122(16):2812-22 - PubMed
  30. Epigenetics. 2015;10(2):103-21 - PubMed
  31. Cell. 2011 Jun 10;145(6):941-955 - PubMed
  32. J Invest Dermatol. 2002 Oct;119(4):783-92 - PubMed
  33. Annu Rev Genet. 1994;28:189-217 - PubMed
  34. Nat Rev Cancer. 2016 Jun;16(6):345-58 - PubMed
  35. Acta Derm Venereol. 2015 May;95(5):516-24 - PubMed
  36. Eur J Cancer. 2016 Jul;62:76-85 - PubMed
  37. Biol Cell. 2015 Dec;107(12 ):440-54 - PubMed
  38. Cancer Res. 2000 Aug 1;60(15):4222-30 - PubMed
  39. Cell. 2012 Jul 6;150(1):12-27 - PubMed
  40. N Engl J Med. 2006 Jul 6;355(1):51-65 - PubMed

Publication Types